๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Tianjin Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV400, Rapamycin Clinical Study of U01๏ผˆssCART-19๏ผ‰ in Patients With B-Cell Lymphoma NCT07093073Phase 11 site๐Ÿ“ Shanghai Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd ยท Tests: ssCART-19 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma NCT05312801Phase 12 sites๐Ÿ“ Cleveland๐Ÿ“ Cleveland Luminary Therapeutics ยท Tests: BAFF CAR-T Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites๐Ÿ“ Boston๐Ÿ“ New York๐Ÿ“ Columbus Reid Merryman, MD ยท Tests: Zanubrutinib, Rituximab, Epcoritamab NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NCT07052305Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: NT-I7, CAR T-cell therapy Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Kansas City PeproMene Bio, Inc. ยท Tests: BAFFR-CAR T cells A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites๐Ÿ“ Fullerton๐Ÿ“ Los Alamitos๐Ÿ“ Santa Monica TORL Biotherapeutics, LLC ยท Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173Phase 120 sites๐Ÿ“ Duarte๐Ÿ“ Santa Monica๐Ÿ“ Louisville Regeneron Pharmaceuticals ยท Tests: Odronextamab, REGN5837 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas NCT07883135Phase 21 site๐Ÿ“ Moscow National Research Center for Hematology, Russia ยท Tests: Glofitamab, Epcoritamab, Polatuzumab Vedotin, Gemcitabine & oxaliplatin, Obinutuzumab Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038Phase 24 sites๐Ÿ“ Mankato๐Ÿ“ Rochester๐Ÿ“ Eau Claire Mayo Clinic ยท Tests: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site๐Ÿ“ Hangzhou He Huang ยท Tests: CTA101 A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL NCT03571568Phase 1, Phase 227 sites๐Ÿ“ Atlanta๐Ÿ“ Louisville๐Ÿ“ Salvador BioInvent International AB ยท Tests: BI-1206, Rituximab, Acalabrutinib A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites๐Ÿ“ La Jolla๐Ÿ“ Boston๐Ÿ“ Rochester AstraZeneca ยท Tests: AZD5492 Hyperfractionated Dual Equivalent Fractionated Radiation Therapy NCT06898905NA1 site๐Ÿ“ New Haven Yale University ยท Tests: Bridging Radiation Therapy A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies NCT06634589Phase 1, Phase 249 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Jacksonville BeOne Medicines ยท Tests: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma NCT07603479Phase 11 site๐Ÿ“ Beijing Jecho Biopharmaceuticals Co., Ltd. ยท Tests: JL19001, subcutaneous injection, 1 ฮผg/kg, JL19001, subcutaneous injection, 5 ฮผg/kg, JL19001, subcutaneous injection,10 โ€ฆ Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ยฑ ASCT in R/R Aggressive B-Cell Lymphoma NCT06996132Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Glofitamab, Chimeric Antigen Receptor T Cells (CAR-T) A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies NCT04532281EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: Murine CD19 CAR-T cells A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma NCT07609030NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration Novel Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy (QH103E) in r/r NHL NCT06838832Phase 1, Phase 21 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: Allogenic CD19-CAR-ฮณฮดT cell, Fludarabine, Cyclophosphamide Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy